Discovery of a multipotent chaperone, 1-(2,6-Difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol with the inhibitory effects on the proliferation of prion, cancer as well as influenza virus.
Chaperone
activation free energy
anti-viral agent
cancer
carbazol
free energy
influenza virus
multipotent
prion
stabilization
Journal
Prion
ISSN: 1933-690X
Titre abrégé: Prion
Pays: United States
ID NLM: 101472305
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
1
10
2021
Statut:
ppublish
Résumé
We previously discovered three carbazole derivatives, GJP14 (1-piperidinylmethyl-2-(1-oxo-6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)-ethan-1-ol) with anti-prion activity, GJC29 (benzylamino-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol) with anti-cancer activity, and THC19 (1-piperidinylmethyl-2-(1,2,3,4-tetrahydrocarnazol-9-yl)-ethan-1-ol) with anti-influenza virus activity. During optimization of GJP14 for the anti-prion activity, we discovered a compound, 1-(2,6-difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol, termed 5Y, had the most strong anti-prion activity among a series of newly synthesized derivatives. Intriguingly, we noticed that 5Y had also the most strong anti-colon cancer as well as the anti-influenza virus activities among derivatives. No significant toxicity of 5Y was observed. These results demonstrate that 5Y is a multipotent lead compound with unusually wide spectrum, and may be applicable to therapeutics targeting multiple diseases.
Identifiants
pubmed: 31971853
doi: 10.1080/19336896.2020.1714372
pmc: PMC6984644
doi:
Substances chimiques
Antineoplastic Agents
0
Carbazoles
0
Prion Proteins
0
carbazole
0P2197HHHN
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-46Références
Antimicrob Agents Chemother. 2009 Feb;53(2):765-71
pubmed: 19015328
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11921-6
pubmed: 17616582
Cell Death Differ. 2017 Oct;24(10):1784-1798
pubmed: 28644435
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8438-42
pubmed: 10411893
J Pharmacol Exp Ther. 2006 May;317(2):562-70
pubmed: 16436501
Biochim Biophys Acta. 2012 Feb;1820(2):90-5
pubmed: 22108550
Proteins. 1995 Nov;23(3):403-14
pubmed: 8710833
Oncol Rep. 2009 Oct;22(4):739-44
pubmed: 19724851
Microbiol Immunol. 2007;51(7):661-9
pubmed: 17641468
Protein Sci. 2016 Dec;25(12):2132-2141
pubmed: 27595938
Bioorg Med Chem Lett. 2008 Jun 15;18(12):3517-21
pubmed: 18511277
Science. 1982 Dec 24;218(4579):1309-11
pubmed: 6815801
Protein Sci. 2013 Jan;22(1):22-34
pubmed: 23081827
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5
pubmed: 18650397
Nature. 1996 Jul 11;382(6587):180-2
pubmed: 8700211
Science. 1994 Apr 22;264(5158):530-1
pubmed: 7909169
Eur J Med Chem. 2011 Nov;46(11):5675-9
pubmed: 21906853
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82
pubmed: 15667143
J Am Chem Soc. 2012 May 23;134(20):8360-3
pubmed: 22574905
J Biol Chem. 2001 Dec 21;276(51):48231-6
pubmed: 11572854
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13937-42
pubmed: 11095725
Nat Biomed Eng. 2019 Mar;3(3):206-219
pubmed: 30948810
Microbes Infect. 2012 Aug;14(9):740-7
pubmed: 22441116
J Mol Recognit. 1996 Jan-Feb;9(1):1-5
pubmed: 8723313
Evid Based Complement Alternat Med. 2012;2012:946867
pubmed: 21876716